By Kathleen Blanchard RN for EmaxHealth.com
Researchers have developed a novel way to control Type 2 diabetes with the oral drug TAK-875. The drug targets cells in the pancreas that stimulate the production of insulin, without the risk of hypoglycemia. Compared to the popular diabetes drug, glimepiride, patients studied had less risk of developing low blood sugar. If levels are normal, TAK-875 has no effect.
Results of a Phase 2 clinical trial, published in the journal Lancet, found the drug worked well to lower HbA1C levels in patients with Type 2 diabetes who failed to keep the disease under control with diet, exercise or the diabetes drug metformin.